Exploring the Therapeutic Potential of B-Cell Modulation in IgAN

The panel examines drug classes targeting the BAFF and APRIL pathways, which play key roles in the production and regulation of IgA-secreting plasma cells. The clinicians discuss how these therapies attempt to reduce the formation of harmful IgA complexes at the source, representing a more upstream approach compared to conventional supportive therapy. They also acknowledge questions surrounding long-term safety, dosing strategies, and patient selection for these newer interventions. Some participants express cautious optimism, noting that early trial data suggest meaningful reductions in proteinuria and stabilization of kidney function. However, they emphasize the importance of real-world experience and monitoring for immune-related side effects, as these therapies affect broader B-cell biology. The conversation highlights how targeted therapies may eventually be used in combination with supportive care to improve outcomes. Overall, the segment reflects a turning point toward therapeutic strategies focused on modifying disease rather than merely slowing progression.